Akebia Therapeutics' stock is being evaluated by analysts after the company released its quarterly earnings results. The company has also made updates on revenue and protocol, and its shareholders have approved certain governance measures and a share increase. Analysts are revising their forecasts and price targets for the company, with some considering its potential as a penny stock and others looking ahead to 2026 and 2027.